# NX Prenatal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nx-prenatal

- Industry: Medical Devices & Equipment
- Headquarters: Louisville, US
- Website: www.nxprenatal.com
- Total disclosed funding: $5M
- Latest round: Series A (Mar 1, 2020)
- Investors on record: 1

## About

NX Prenatal Inc. focuses on innovative blood testing solutions for maternal and fetal health, aiming to enhance prenatal care and prevent complications associated with pregnancy.NX Prenatal Inc. specializes in advanced maternal and fetal health through innovative blood testing. The company, founded by Brian Brohman, is headquartered in Louisville, US. In March 2020, NX Prenatal raised USD 5.00 mn in Series A funding from Solas BioVentures, marking a significant investment to support its operations and development.NX Prenatal specializes in advanced maternal and fetal health through its innovative blood testing approach. The company offers services that provide critical insights into prenatal health and aim to prevent complications such as preterm birth and preeclampsia. Their first-trimester blood testing, which can be performed as early as 9-13 weeks of pregnancy, delivers tailored maternal health information that is essential for early risk stratification. This service is designed for expectant mothers, obstetricians, and healthcare providers seeking to improve maternal and fetal outcomes. NX Prenatal collaborates with leading institutions to develop molecular tests that enhance personalized care, focusing on markets in the United States and potentially extending to regions with a high demand for prenatal health innovations.NX Prenatal generates revenue through direct-to-consumer sales as well as partnerships within the healthcare sector. Their core offerings, including the first-trimester blood tests and diagnostic services related to conditions like preeclampsia and placenta accreta, are structured as fee-for-service transactions with healthcare providers and expectant mothers. The testing services are billed per test, allowing flexibility for physicians to integrate these diagnostics into their practices. Furthermore, NX Prenatal's partnerships with clinical and research institutions may involve collaborative projects and shared financial arrangements, enhancing their market reach and fostering further innovation in prenatal health solutions.NX Prenatal plans to leverage the USD 5.00 mn raised in March 2020 to enhance its product offerings and expand its presence in the maternal and fetal health markets. The company is focused on developing new molecular tests and aims to increase its market penetration in the United States, with potential expansion into other regions with high demand for prenatal innovations by the end of 2022.

## Funding rounds

- Series A, Mar 1, 2020, $5M — Solas BioVentures

## Investors

- Solas BioVentures (https://capitalatlas.ai/funds/solas-bioventures) — Series A